Eloxx Pharmaceuticals (ELOX) Stock Price, News & Analysis

Company Overview

Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel therapies for rare genetic diseases caused by nonsense mutations. The company’s proprietary technology platform is designed to selectively promote ribosomal read-through of premature stop codons, enabling the restoration of full-length functional proteins. Eloxx’s lead candidate, ELX-02, is being evaluated in multiple clinical trials for its potential to treat cystic fibrosis patients with specific nonsense mutations as well as to address nephropathic cystinosis, a rare lysosomal storage disorder.

ELX-02 has demonstrated promising preclinical activity, showing the ability to induce production of functional protein in relevant cellular and animal models. The company has completed an initial Phase 1 study in healthy volunteers and has advanced to Phase 2 trials in patients with cystic fibrosis, where it is assessing safety, tolerability and preliminary efficacy. In parallel, Eloxx is working toward clinical studies in nephropathic cystinosis, leveraging the same read-through approach to correct CTNS gene defects that underlie the disease.

Headquartered in New York, Eloxx Pharmaceuticals leverages collaborations with leading academic research centers and contract research organizations to support its development programs. The company’s management team brings together experienced drug developers with expertise in rare disease research, clinical development and regulatory strategy. With a focus on precision medicine for genetically defined patient populations, Eloxx aims to address significant unmet needs in rare disease therapeutics.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.00 to $0.75
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 1,618 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ELOX Stock Analysis - Frequently Asked Questions

How were Eloxx Pharmaceuticals' earnings last quarter?

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) released its quarterly earnings results on Monday, April, 3rd. The company reported ($2.92) earnings per share for the quarter, beating the consensus estimate of ($2.97) by $0.05.

How do I buy shares of Eloxx Pharmaceuticals?

Shares of ELOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Eloxx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eloxx Pharmaceuticals investors own include Tesla (TSLA), ADMA Biologics (ADMA), Adverum Biotechnologies (ADVM), Assertio (ASRT), Fulcrum Therapeutics (FULC), Acasti Pharma (ACST) and Akebia Therapeutics (AKBA).

Company Calendar

• Last Earnings: 4/03/2023
• Today: 7/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ELOX
• CIK: 1035354
• Web: www.eloxxpharma.com
• Phone: (781) 577-5300
• Fax: 908-864-4440
• Employees: 30
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 3,143,000
• Free Float: 2,508,000
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -1,536.27